About: http://data.cimple.eu/news-article/54e9a502e0b85ec7cb1bbf3441fc074d8890f38179f77bf679528c89     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • German firm BioNTech said Tuesday it was on track to manufacture 2.5 billion doses of its Covid-19 vaccine this year with US partner Pfizer, 25 percent more than expected. The company said the boost would allow it to "address increased demand" as countries around the world race to contain new, more contagious virus variants. The higher output was driven by the recent launch of a new production site in the German city of Marburg, which is now one of the world's largest mRNA vaccine manufacturing plants, it said. The plant will eventually produce up to one billion Covid jabs a year, once fully operational. The first batches from Marburg will be delivered in the second half of April, the statement said. Over the first half of 2021 alone, BioNTech expects it to churn out 250 million doses. The vaccine is also being produced at a Pfizer plant in Belgium and at three sites in the United States. BioNTech said improved efficiency and new cooperation agreements with outside partners had also helped lift its vaccine target, as had the regulatory nod allowing vaccinators to extract six instead of just five doses from a single BioNTech/Pfizer vial. The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 vaccine to be approved in the West late last year. BioNTech said it had delivered more than 200 million doses to "more than 65 countries and regions" by March 23. Two doses are required for optimal protection. Recent studies have shown that the jab is not only highly effective in protecting against Covid, it also provides protection against transmission of the virus. "We are already seeing the first signs of vaccine associated reduction of COVID-19 cases and mortality in multiple countries," said BioNTech CEO and co-founder Ugur Sahin. "We will continue to focus on innovating in the COVID-19 field by advancing new formulations and addressing vaccine variants," he added. The company's vaccine has also been buoyed by a green light from the European Medicines Agency last week allowing BioNTech/Pfizer vials to be kept at normal freezer temperatures for short periods, simplifying the jab's complex cold chain logistics. In Tuesday's statement, BioNTech announced a net profit of 15.2 million euros for 2020, compared with a 179-million-euro loss in 2019. mfp/hmn/txw
schema:headline
  • BioNTech raises Covid vaccine output goal to 2.5 bn doses
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software